logo-loader

Algae.Tec’s shares rise after licensing unique pharmaceutical delivery technology

Published: 13:29 12 Feb 2018 AEDT

a lab technician
Algae oil will be the base component

Algae.Tec Ltd’s (ASX:AEB) shares are trading circa 13% higher intra-day after licensing a patented mini emulsion-based delivery platform for pharmaceutical application.

The company has signed an agreement with a private Australian-based pharmaceutical delivery company, NS Technologies (NST) for the delivery platform technology.

Lower dosage with an effective outcome

The technology is one where a ‘mini-emulsion’ was developed to allow complex molecules to penetrate the epidermis skin layer, and enter the subdermal layer of the human body.

The mini-emulsion droplets filter through the epidermal layer, in an effective, “slow release” manner, allowing lower dosages, with an effective outcome.

This mini-emulsion base component requires a selected vegetable oil, which is ideally suited to specific algal oils.

Algae.Tec’s algal oils could be the base component

Under the agreement, Algae.Tec will acquire 19.9% of NST and exclusively license NST’s delivery platform technology for use across any medical application developed by Algae.Tec.

NST has also agreed to use AEB’s algae oil as the base component of its emulsion delivery platform.

The companies are aiming to develop a range of mini-emulsion pharmaceutical products for both human and veterinary purposes using selected algal oils.

READ: Algae.Tec to boost cash for medical cannabis cultivation plans

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

5 hours, 27 minutes ago